Cargando…
Corrections
This article has been corrected. Please see J Manag Care Spec Pharm, 2018 Sep;24(9-a):S14-S29.
Autores principales: | Handelsman, Yehuda, Wyne, Kathleen, Cannon, Anthony, Shannon, Michael, Schneider, Doron |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401970/ https://www.ncbi.nlm.nih.gov/pubmed/30806138 http://dx.doi.org/10.18553/jmcp.2018.24.11.1196a |
Ejemplares similares
-
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists
por: Handelsman, Yehuda, et al.
Publicado: (2018) -
Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications
por: Heile, Michael, et al.
Publicado: (2018) -
Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus
por: Billings, Liana K., et al.
Publicado: (2018) -
Burden of Illness in Type 2 Diabetes Mellitus
por: Cannon, Anthony, et al.
Publicado: (2018) -
Corrections
Publicado: (2018)